Neuphoria Therapeutics Inc. NEUP 深 沪
等待开盘 05-21 09:30:00 美东时间
4.85
+0.080
+1.68%
华盛通- 最 高4.99
- 今 开4.71
- 成交量 2.90万股
- 最 低 4.48
- 昨 收 4.77
- 总市值 2614.58万
- 52周最高 21.4004
- 市盈率 静 --
- 换手率 0.54%
- 52周最低 3.645
- 委 比 -62.76%
- 总股本 539.09万
- 历史最高 21.4004
- 量 比 1.21
- 振 幅 10.69%
- 历史最低 2.90
- 每 手 1
- 风险率 3.49%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Deal Dispatch: GoPro Retains Houlihan Lokey In Strategic Review, Brookfield Buys World Freight Company, YesCare Corp. Bankruptcy
Major M&A deals this week include: LVMH agrees to sell Marc Jacobs to WHP Global, 365 Markets buys Cantaloupe, Apollo mulls sale of MFIC.
05-16 02:44
HC Wainwright & Co. Downgrades Neuphoria Therapeutics to Neutral
HC Wainwright & Co. analyst Joseph Pantginis downgrades Neuphoria Therapeutics (NASDAQ:NEUP) from Buy to Neutral.
05-16 01:34
Neuphoria Therapeutics Q3 EPS $(0.09) Beats $(0.97) Estimate
Neuphoria Therapeutics (NASDAQ:NEUP) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.97) by 90.72 percent. This is a 101.37 percent decrease over earnings of $6.55 per
05-15 21:23
Neuphoria Therapeutics posts Q4 income before income taxes of USD 1.83 million, reversing a loss
Neuphoria Therapeutics posts Q4 income before income taxes of USD 1.83 million, reversing a loss Neuphoria Therapeutics Inc. reported income before income taxes of USD 1.83 million for the quarter ended December 31, 2025, compared to a loss in the prior-year period. Revenue declined during the quart
02-18 04:58
美股大行评级 | 高盛上调梅西百货目标价至22美元！ 摩根大通上调美国铝业公司目标价至45美元
今日重点评级关注：Stifel：维持X4 Pharmaceuticals"买入"评级，目标价从7.5美元升至10美元；花旗：维持UP Fintech Holding"买入"评级，目标价从17.4美元升至17.5美元
2025-12-08 08:34
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan To Protect Integrity Of Process; Board Declares Dividend Of One Preferred Share Purchase Right For Each Outstanding Share Of Co
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (NASDAQ:NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders,today announced that its Board of Directors
2025-10-28 04:53
Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process
Neuphoria Therapeutics announced its Board has adopted a limited-duration stockholder rights plan to safeguard against rapid accumulation of its shares by investors. The plan aims to protect shareholder interests, ensure fair participation in strategic reviews, and prevent control without a premium. It does not hinder the Board from exploring strategic alternatives. The rights will trigger if any entity gains 15% ownership without Board approval,...
2025-10-27 20:29
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers iBio (NASDAQ:IBIO) stock increased by 28.8% to $1.15 during Monday's a...
2025-10-21 05:08
Neuphoria's AFFIRM-1 Trial For Social Anxiety Fails To Meet Endpoints; Company Initiates Strategic Review
AFFIRM-1 trial did not meet primary endpoint or secondary endpointsCompany to conduct strategic review of portfolio and business operationsBURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc.
2025-10-21 04:19
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
Neuphoria Therapeutics Inc. announced that its AFFIRM-1 Phase 3 trial for BNC210 in treating social anxiety disorder (SAD) did not meet its primary or secondary endpoints. The company plans to discontinue further development of the SAD program and evaluate next steps for BNC210 in post-traumatic stress disorder (PTSD). Neuphoria will conduct a strategic review of its operations and portfolio. The company has $14.2 million in cash and expects to f...
2025-10-20 20:15
